Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases

Bioactive compounds are comprised of small quantities of extra nutritional constituents providing both health benefits and enhanced nutritional value, based on their ability to modulate one or more metabolic processes. Plant-based diets are being thoroughly researched for their cardiovascular proper...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rakesh K. Sindhu, Annima Goyal, Evren Algın Yapar, Simona Cavalu
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
T
Acceso en línea:https://doaj.org/article/127dd05075cf439d859809af2055da91
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:127dd05075cf439d859809af2055da91
record_format dspace
spelling oai:doaj.org-article:127dd05075cf439d859809af2055da912021-11-25T16:43:07ZBioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases10.3390/app1122110312076-3417https://doaj.org/article/127dd05075cf439d859809af2055da912021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3417/11/22/11031https://doaj.org/toc/2076-3417Bioactive compounds are comprised of small quantities of extra nutritional constituents providing both health benefits and enhanced nutritional value, based on their ability to modulate one or more metabolic processes. Plant-based diets are being thoroughly researched for their cardiovascular properties and effectiveness against cancer. Flavonoids, phytoestrogens, phenolic compounds, and carotenoids are some of the bioactive compounds that aim to work in prevention and treating the cardiovascular disease in a systemic manner, including hypertension, atherosclerosis, and heart failure. Their antioxidant and anti-inflammatory properties are the most important characteristics that make them favorable candidates for CVDs treatment. However, their low water solubility and stability results in low bioavailability, limited accessibility, and poor absorption. The oral delivery of bioactive compounds is constrained due to physiological barriers such as the pH, mucus layer, gastrointestinal enzymes, epithelium, etc. The present review aims to revise the main bioactive compounds with a significant role in CVDs in terms of preventive, diagnostic, and treatment measures. The advantages of nanoformulations and novel multifunctional nanomaterials development are described in order to overcome multiple obstacles, including the physiological ones, by summarizing the most recent preclinical data and clinical trials reported in the literature. Nanotechnologies will open a new window in the area of CVDs with the opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues.Rakesh K. SindhuAnnima GoyalEvren Algın YaparSimona CavaluMDPI AGarticlebioactive compoundscardiovascularnanodeliverybioavailabilityTechnologyTEngineering (General). Civil engineering (General)TA1-2040Biology (General)QH301-705.5PhysicsQC1-999ChemistryQD1-999ENApplied Sciences, Vol 11, Iss 11031, p 11031 (2021)
institution DOAJ
collection DOAJ
language EN
topic bioactive compounds
cardiovascular
nanodelivery
bioavailability
Technology
T
Engineering (General). Civil engineering (General)
TA1-2040
Biology (General)
QH301-705.5
Physics
QC1-999
Chemistry
QD1-999
spellingShingle bioactive compounds
cardiovascular
nanodelivery
bioavailability
Technology
T
Engineering (General). Civil engineering (General)
TA1-2040
Biology (General)
QH301-705.5
Physics
QC1-999
Chemistry
QD1-999
Rakesh K. Sindhu
Annima Goyal
Evren Algın Yapar
Simona Cavalu
Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
description Bioactive compounds are comprised of small quantities of extra nutritional constituents providing both health benefits and enhanced nutritional value, based on their ability to modulate one or more metabolic processes. Plant-based diets are being thoroughly researched for their cardiovascular properties and effectiveness against cancer. Flavonoids, phytoestrogens, phenolic compounds, and carotenoids are some of the bioactive compounds that aim to work in prevention and treating the cardiovascular disease in a systemic manner, including hypertension, atherosclerosis, and heart failure. Their antioxidant and anti-inflammatory properties are the most important characteristics that make them favorable candidates for CVDs treatment. However, their low water solubility and stability results in low bioavailability, limited accessibility, and poor absorption. The oral delivery of bioactive compounds is constrained due to physiological barriers such as the pH, mucus layer, gastrointestinal enzymes, epithelium, etc. The present review aims to revise the main bioactive compounds with a significant role in CVDs in terms of preventive, diagnostic, and treatment measures. The advantages of nanoformulations and novel multifunctional nanomaterials development are described in order to overcome multiple obstacles, including the physiological ones, by summarizing the most recent preclinical data and clinical trials reported in the literature. Nanotechnologies will open a new window in the area of CVDs with the opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues.
format article
author Rakesh K. Sindhu
Annima Goyal
Evren Algın Yapar
Simona Cavalu
author_facet Rakesh K. Sindhu
Annima Goyal
Evren Algın Yapar
Simona Cavalu
author_sort Rakesh K. Sindhu
title Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
title_short Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
title_full Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
title_fullStr Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
title_full_unstemmed Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
title_sort bioactive compounds and nanodelivery perspectives for treatment of cardiovascular diseases
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/127dd05075cf439d859809af2055da91
work_keys_str_mv AT rakeshksindhu bioactivecompoundsandnanodeliveryperspectivesfortreatmentofcardiovasculardiseases
AT annimagoyal bioactivecompoundsandnanodeliveryperspectivesfortreatmentofcardiovasculardiseases
AT evrenalgınyapar bioactivecompoundsandnanodeliveryperspectivesfortreatmentofcardiovasculardiseases
AT simonacavalu bioactivecompoundsandnanodeliveryperspectivesfortreatmentofcardiovasculardiseases
_version_ 1718413001056321536